A5050622223- CNS Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
- Venous Thromboembolism Diagnosis and Management
- Neutropenia and Cancer Infections
- Cardiac tumors and thrombi
- Lung Cancer Research Studies
- Glioma Diagnosis and Treatment
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Viral-associated cancers and disorders
Oulu University Hospital
2016-2024
University of Oulu
2021
Abstract Background Rituximab‐based combinations are the standard of care in diffuse large B‐cell lymphoma (DLBCL) and follicular (FL). Despite being on market for over 20 years, some adverse effects associated with use rituximab not well known. Drug‐induced interstitial pneumonitis (DIP) is a potentially fatal complication treatment. Granulocyte colony‐stimulating factors (G‐CSF) supportive agents commonly used to prevent neutropenic infections. G‐CSF reported have pulmonary toxicity, but...
Abstract Bulky and residual tumor are considered to increase the risk of relapse in diffuse large B‐cell lymphoma (DLBCL) patients. Radiotherapy is conventionally used reduce risk, but evidence controversial. We performed a retrospective analysis evaluate significance bulky treated with or without radiotherapy DLBCL analyzed 312 patients from 2010‐2017 Oulu University Hospital. A was detected 123 55 these (44.3%) received consolidative radiation therapy (RT) tumor. Residual meeting required...
Abstract The application of positron emission tomography (PET)‐computed (CT) in treatment response evaluation has increased diffuse large B‐cell lymphoma (DLBCL), although its predictive value is controversial. We retrospectively analyzed the rate false‐positive PET‐CTs performed as interim ( n = 94) and end‐of‐treatment 8) assessments among 102 DLBCL patients treated during 2010–2017 at Oulu University Hospital. In PET‐CT Deauville score ≥4 was regarded positive. A biopsy on 35 patients,...
Abstract Background Venous thromboembolic events (VTEs) remain a major cause of mortality and morbidity among lymphoma patients. Accurate risk-prediction models are lacking, however, especially in the high VTE risk subgroup diffuse large B-cell (DLBCL). The relationship between patient-, disease- treatment-related factors is yet incompletely defined this disease entity. Methods In retrospective study, we analyzed for VTEs DLBCL patients treated with first-line (1L) chemoimmunotherapy Kuopio...
Abstract Venous thromboembolic events (VTEs) remain a major cause of mortality and morbidity among lymphoma patients. In this retrospective study, we analyzed the risk factors for VTEs in DLBCL (diffuse large B-cell lymphoma) patients treated with first-line (1L) chemoimmunotherapy Kuopio Oulu University Hospitals (2010–2019).VTE occurred 17.2% (n = 59) whole population, seven during anticoagulant therapy. Statistically significant VTE included age > 65 years, ECOG (Eastern Cooperative...